Jarrett Paul, Camargo Carlos Arturo, Coomarasamy Christin, Scragg Robert
a Department of Epidemiology and Biostatistics , The University of Auckland , Auckland , New Zealand.
b Department of Medicine , The University of Auckland , Auckland , New Zealand.
J Dermatolog Treat. 2018 Jun;29(4):324-328. doi: 10.1080/09546634.2017.1373735. Epub 2017 Sep 19.
To investigate the clinical effect of vitamin D supplementation on psoriasis from a community-dwelling population.
Participants with psoriasis in a large randomized controlled trial examining the effect of vitamin D supplementation (100,000 IU monthly) in adults aged 50-84 years were invited to participate in a psoriasis sub-study over 12 months. The primary outcome was the Psoriasis Area and Severity Index (PASI) and secondary outcomes were Physicians Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Psoriasis Disability Index (PDI). Trial identification number ACTRN12611000402943.
Twenty-three were allocated to vitamin D and 42 to placebo. There was no significant difference at baseline between the two groups. Mean (SD) baseline 25-hydroxyvitamin D was 65.7 (25.7) nmol/L. There were no significant differences (p > .05) between the groups in all of the psoriasis outcome measures. Mean scores [95% CI] at 12 months for the Placebo versus Vitamin D groups: PASI 2.2 [1.4, 3.0] versus 2.1 [1.0, 3.2]; PGA 1.4 [1.1, 1.7] versus 1.5 [1.1, 1.9]; PDI 2.1 [0.9, 3.2] versus 1.9 [0.4, 3.4]; and DLQI 2.5 [1.4, 3.6] versus 2.0 [0.5, 3.4].
Vitamin D supplementation (100,000 IU per month) is not recommended as a treatment for mild psoriasis.
研究补充维生素D对社区居民银屑病的临床疗效。
在一项大型随机对照试验中，邀请年龄在50 - 84岁的成年银屑病患者参加为期12个月的银屑病子研究，该试验旨在研究补充维生素D（每月100,000国际单位）的效果。主要结局指标为银屑病面积和严重程度指数（PASI），次要结局指标为医生整体评估（PGA）、皮肤病生活质量指数（DLQI）和银屑病残疾指数（PDI）。试验识别号为ACTRN12611000402943。
23人被分配到维生素D组，42人被分配到安慰剂组。两组在基线时无显著差异。平均（标准差）基线25 - 羟基维生素D为65.7（25.7）nmol/L。在所有银屑病结局指标方面，两组之间均无显著差异（p > 0.05）。安慰剂组与维生素D组在12个月时的平均得分[95%置信区间]：PASI为2.2 [1.4, 3.0] 对2.1 [1.0, 3.2]；PGA为1.4 [1.1, 1.7] 对1.5 [1.1, 1.9]；PDI为2.1 [0.9, 3.2] 对1.9 [0.4, 3.4]；DLQI为2.5 [1.4, 3.6] 对2.0 [0.5, 3.4]。
不建议将每月补充100,000国际单位维生素D作为轻度银屑病的治疗方法。
